Stockreport

Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases [Yahoo! Finance]

ASAHI KAISEI CRP UNSP/ADR  (AHKSY) 
NASDAQ:AMEX Investor Relations: asahi-kasei.co.jp/asahi/en/ir
PDF AK1940, a novel peptide-based investigational compound developed to address significant unmet medical needs in patients with autoimmune diseases. The trial is being cond [Read more]